April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Correlation Between Change In Visual Acuity (va) And Lesion Size After Two Regimes Of Intravitreal Bevacizumab In Age Related Macular Degeneration(armd) With Minimally Classic And Occult Choroidal Neovascularisation
Author Affiliations & Notes
  • Nitin Jain
    Ophthalmology, Frimley Park Hospital NHS Foundation Trust, Camberly, United Kingdom
  • Manju Chandran, Sr.
    Ophthalmology, Frimley Park Hospital NHS Foundation Trust, Camberly, United Kingdom
  • Narendran Nair
    Ophthalmology, Frimley Park Hospital NHS Foundation Trust, Camberly, United Kingdom
  • Gulrez Ansari
    Ophthalmology, Frimley Park Hospital NHS Foundation Trust, Camberly, United Kingdom
  • Leena Bhat
    Ophthalmology, Frimley Park Hospital NHS Foundation Trust, Camberly, United Kingdom
  • Lorraine North
    Ophthalmology, Frimley Park Hospital NHS Foundation Trust, Camberly, United Kingdom
  • Emily Turton
    Ophthalmology, Frimley Park Hospital NHS Foundation Trust, Camberly, United Kingdom
  • Geeta Menon
    Ophthalmology, Frimley Park Hospital NHS Foundation Trust, Camberly, United Kingdom
  • Footnotes
    Commercial Relationships  Nitin Jain, None; Manju Chandran, Sr., None; Narendran Nair, None; Gulrez Ansari, None; Leena Bhat, None; Lorraine North, None; Emily Turton, None; Geeta Menon, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 1688. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Nitin Jain, Manju Chandran, Sr., Narendran Nair, Gulrez Ansari, Leena Bhat, Lorraine North, Emily Turton, Geeta Menon; Correlation Between Change In Visual Acuity (va) And Lesion Size After Two Regimes Of Intravitreal Bevacizumab In Age Related Macular Degeneration(armd) With Minimally Classic And Occult Choroidal Neovascularisation. Invest. Ophthalmol. Vis. Sci. 2011;52(14):1688. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To investigate the correlation between change in VA and lesion size after two regimes of intravitreal Bevacizumab in ARMD with Minimally Classic and Occult choroidal neovascularisation.

Methods: : Retrospective review of 88 eyes (87 patients) treated with intravitreal injection of Bevacizumab were randomised into two groups. Group I had intravitreal Bevacizumab 1.25mg administered 6 weekly for three visits and then Pro Re Nata (PRN). Group II had intravitreal Bevacizumab PRN after the first dose. Follow up was 6 weekly for a period of 1 year . Changes in VA as measured by Early Treatment Diabetic Retinopathy Study (ETDRS) charts at baseline and after 12 months were analysed. We also compared the differences in the lesion size before and after treatment. In addition we examined the correlation of the change in VA with lesion size.

Results: : Mean change in VA before and after treatment showed a 0.66 improvement for Group 1, and 2.41 deterioration for Group 2. Visual acuity before and after treatment was not significantly different for either group (Group 1: p=.767; Group 2: p=.232, paired t-test). Mean change in lesion size before and after treatment showed an improvement, reducing by 1.87 in Group 1 and 3.00 in Group 2. Lesion size for both groups was significantly reduced (Group 1: p<.001; Group 2: p<.001, Wilcoxon signed ranks test). A correlation was observed between the change in VA and change in lesion size for Group 1, but not Group 2 (Group 1: r= -.352, p<.05; Group 2 r=3.22, p =.052, Pearsons correlation).

Conclusions: : VA showed improvement in Group I with significant reduction in lesion size. In addition a correlation was observed between the change in VA and lesion size in Group I. In our small study Group I with initial loading dose was more effective than Group 2.

Keywords: age-related macular degeneration • choroid: neovascularization • clinical (human) or epidemiologic studies: outcomes/complications 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×